GTG developed and selling breast cancer tools, its share price skyrocketed, but now they intend to ditch the test kits. I don't think blood tests would be main stream, lots of other equipment tools are the key to the test.
BIT is different, if BIT225 commercialised (57.6% successful rate from Phase 2 to FDA approval according to FDAreview.gov statistic research), then targeting real US$20b/year HIV market, it's a completely different story, imo.
gap closed, page-19
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
